Cancers (Nov 2020)

The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany—Cross-Sectional Results of a Nationwide Observational Study (PROSa)

  • Martin Eichler,
  • Leopold Hentschel,
  • Stephan Richter,
  • Peter Hohenberger,
  • Bernd Kasper,
  • Dimosthenis Andreou,
  • Daniel Pink,
  • Jens Jakob,
  • Susanne Singer,
  • Robert Grützmann,
  • Stephen Fung,
  • Eva Wardelmann,
  • Karin Arndt,
  • Vitali Heidt,
  • Christine Hofbauer,
  • Marius Fried,
  • Verena I. Gaidzik,
  • Karl Verpoort,
  • Marit Ahrens,
  • Jürgen Weitz,
  • Klaus-Dieter Schaser,
  • Martin Bornhäuser,
  • Jochen Schmitt,
  • Markus K. Schuler,
  • the PROSa Study Group

DOI
https://doi.org/10.3390/cancers12123590
Journal volume & issue
Vol. 12, no. 12
p. 3590

Abstract

Read online

Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60–66%), physical (60%, 95% CI 57–62%), role functioning (51%, 95% CI 48–54%), and pain (56%, 95% CI 53–59%) and fatigue (51%, 95% CI 48–54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.

Keywords